United States: FDA Issues Draft Guidance On Pre-Submission Facility Correspondence - A Way To Reduce FDA Action Times For Priority ANDAs

The U.S. Food and Drug Administration (FDA) has released a draft guidance 1, entitled "ANDAs: Pre-Submission Facility Correspondence Associated with Priority Submissions," that provides recommendations regarding use of a pre-submission facility correspondence process (PFC) to help prospective generic drug applicants reduce approval time for priority abbreviated new drug applications (ANDAs), including priority original ANDAs, priority major ANDA amendments and priority ANDA prior approval supplements (PAS). 

What Is PFC?

PFC is a mechanism that a prospective generic drug applicant can use to expedite approval of its priority ANDAs by providing FDA with information regarding its manufacturing and bioequivalence facilities. This information will allow FDA to determine whether it needs to inspect the generic drug applicant's facilities and, if needed, will enable FDA to initiate early inspection planning.

FDA Goals for Standard and Priority ANDAs

FDA has set a goal to review and act on priority ANDAs two months faster if the submission meets all PFC requirements. The table2 below compares timelines for FDA's goals regarding various types of submissions with or without PFC.

Submission Type

Goal for FDA to Review and Act on Submission (from Submission Date)

Standard Original ANDAs

90 percent within 10 months

Priority Original ANDAs

90 percent within eight months if the applicant is successful3 in PFC process

90 percent within 10 months if the applicant does not use PFC process or is unsuccessful in meeting its requirements

Standard Major ANDA Amendments

90 percent within eight months if preapproval inspection is not required

90 percent within 10 months if preapproval inspection is required

Priority Major ANDA Amendments

90 percent within six months if preapproval inspection is not required

90 percent within eight months if preapproval inspection is required and applicant is successful in PFC process

90 percent within 10 months if preapproval inspection is required and applicant is unsuccessful in PFC process

Standard and Priority Minor ANDA Amendments

90 percent within three months

Standard PAS and Standard PAS Major Amendments

90 percent within six months if preapproval inspection is not required

90 percent within 10 months if preapproval inspection is required

Priority PAS and Priority PAS Major Amendments

90 percent within four months if preapproval inspection is not required

90 percent within eight months if preapproval inspection is required and applicant is successful in PFC process

90 percent within 10 months if preapproval inspection is required and applicant is unsuccessful in PFC process

Standard and Priority Minor PAS

90 percent within three months of submission date

FDA's Guidance

The agency's guidance "establishes FDA's expectations for the content, timing, and assessment of the PFC."  A generic drug applicant can benefit from FDA's shorter goal date for action for its priority ANDA if the facility information in PFC is provided two months ahead of the priority ANDA submission and is complete, accurate and unchanged

The draft guidance provides detailed instructions for ANDA applicants to follow when submitting PFCs. According to FDA, "[a] complete and accurate PFC allows [it] to begin the facility assessment process in advance of the planned ANDA submission. This critical 2 month lead time provides the Agency the opportunity to determine whether facility inspections will be needed, and when they are, to initiate inspection planning earlier in the review of the ANDA [...]."

In order to be complete and accurate, the PFC should include, among other things, a thorough description of the manufacturing process and testing facility, all study information, statement of ANDA eligibility for priority review, bioequivalence summary and site/organization information.4  

Timing of a PFC submission is critical. If the PFC is submitted less than two months before a priority ANDA, then it will not generally be eligible for FDA's shorter goal date. Moreover, FDA recommends that "Applicants should submit the [priority] ANDA no more than 3 months after submission of the PFC to reduce the likelihood of changes that result in the loss of eligibility for the shorter goal date." 

Given FDA's reluctance to allow submissions that do not meet its criteria, it is advisable for ANDA applicants seeking benefit of PFC to follow FDA's guidelines as closely as possible. If an applicant's first PFC is denied, the Agency is unlikely to review a second PFC for the same submission.

For Further Information

If you have any questions about this Alert or would like more information, please contact Frederick (Rick) R. Ball, Neelaabh Shankar, Ph.D., any of the attorneys in our Pharmaceutical, Medical Device, Pharmacy and Food industry group or the attorney in the firm with whom you are regularly in contact.


1 ANDAs: Pre-Submission Facility Correspondence Associated with Priority Submissions Guidance for Industry (https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm563507.pdf)

2 Modified from GDUFA reauthorization performance goals and program enhancements fiscal years 2018-2022 (https://www.fda.gov/downloads/forindustry/userfees/genericdruguserfees/ucm525234.pdf)

3 An applicant may be successful in PFC process if the PFC is submitted two months prior to the submission date of priority ANDA and the PFC is found to be complete, accurate, and remains unchanged.

4 Detailed information is provided in the Draft Guidance under Section IV.


This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions